全球婦科藥品市場規模、佔有率、趨勢和成長分析報告（2026-2034）

婦科藥品市場預計將從 2025 年的 780.6 億美元成長到 2034 年的 1,219.4 億美元，2026 年至 2034 年的複合年成長率為 5.08%。

受女性健康意識增強和生殖系統疾病發病率上升的推動，全球婦科藥品市場正穩定成長。子宮內膜異位症、卵巢症候群（PCOS）和更年期症狀等疾病的出現，推動了對專業婦科藥物的需求。醫療保健服務覆蓋範圍的擴大也進一步促進了全球市場的發展。

關鍵成長要素包括荷爾蒙療法的進步和診斷技術的改進。人們對計劃生育和生育治療日益成長的興趣也促進了藥物使用量的成長。此外，醫療保健支出的增加和政府關注孕產婦健康的政策也在推動市場成長。

鑑於標靶治療和個人化醫療研究的進展，前景依然樂觀。新興市場憑藉著不斷完善的醫療基礎設施和日益增強的健康意識，蘊藏著巨大的發展機會。由於更安全、更有效的藥物配方不斷創新，全球婦科市場可望維持長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球婦科藥物市場：依治療方法

• 市場分析、洞察與預測
• 荷爾蒙療法
• 非荷爾蒙療法

第5章：全球婦科藥物市場：依適應症分類

• 市場分析、洞察與預測
• 婦科癌症
• 子宮內膜異位症
• 女性不孕症
• 更年期症狀
• 婦科感染疾病
• 卵巢症候群
• 避孕（節育）
• 其他

第6章 全球婦科藥品市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球婦科藥品市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Allergan Plc
  • Amgen Inc
  • Bayer AG
  • Merck & Co. Inc
  • Pfizer Inc
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Ferring Holding SA
  • TherapeuticsMD Inc
  • AbbVie Inc
  • Pfizer Inc
  • AstraZeneca

The Gynecology Drugs Market size is expected to reach USD 121.94 Billion in 2034 from USD 78.06 Billion (2025) growing at a CAGR of 5.08% during 2026-2034.

The Global Gynecology Drugs Market is growing steadily due to rising awareness about women's health and increasing prevalence of reproductive disorders. Conditions such as endometriosis, polycystic ovary syndrome (PCOS), and menopausal symptoms are driving demand for specialized gynecological medications. Expanding access to healthcare services is further supporting market expansion worldwide.

Major growth drivers include advancements in hormonal therapies and improved diagnostic techniques. Growing emphasis on family planning and fertility treatments is also contributing to increased drug utilization. Additionally, rising healthcare spending and government initiatives focused on maternal health are strengthening market growth.

Future prospects remain positive as research into targeted therapies and personalized treatments advances. Emerging markets are expected to offer substantial opportunities due to improving healthcare infrastructure and rising health awareness. Continued innovation in safer and more effective drug formulations will likely sustain long-term growth in the global gynecology drugs market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• Hormonal Therapy
• Non-Hormonal Therapy

By Indication

• Gynecological Cancers
• Endometriosis
• Female Infertility
• Menopausal Disorder
• Gynecology Infections
• Polycystic Ovary Syndrome
• Contraception (Birth Control)
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Allergan plc, Amgen Inc, Bayer AG, Merck Co Inc, Pfizer Inc, Eli Lilly and Company, F HoffmannLa Roche Ltd, Ferring Holding SA, TherapeuticsMD Inc, AbbVie Inc, Pfizer Inc, AstraZeneca
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GYNECOLOGY DRUGS MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GYNECOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Gynecological Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Endometriosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Female Infertility Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Menopausal Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gynecology Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Polycystic Ovary Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Contraception (Birth Control) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GYNECOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GYNECOLOGY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutics
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutics
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutics
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutics
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutics
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GYNECOLOGY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Allergan Plc
  • 9.2.2 Amgen Inc
  • 9.2.3 Bayer AG
  • 9.2.4 Merck & Co. Inc
  • 9.2.5 Pfizer Inc
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 Ferring Holding SA
  • 9.2.9 TherapeuticsMD Inc
  • 9.2.10 AbbVie Inc
  • 9.2.11 Pfizer Inc
  • 9.2.12 AstraZeneca